Biocon

In 1978, a 25-year-old fermentation specialist in Bengaluru persuaded a small Irish company to form a joint venture and started a biotechnology business with about US$10,000. Kiran Mazumdar-Shaw set up Biocon in what was effectively a garage, making industrial enzymes including papain. Biotechnology was not a category India recognised at the time. She invented it as a business one year at a time.

From industrial enzymes to a global biosimilars platform

The first decade was about enzymes and exports: in 1979 Biocon became the first Indian company to manufacture and export enzymes to the US and Europe. The pivot to pharmaceuticals came in stages. In 1998, Unilever sold its Biocon stake to the Indian promoters and Biocon became independent. In 2001, Biocon became the first Indian company approved by the USFDA for lovastatin manufacture. In 2003, it became the first company worldwide to develop human insulin on a pichia expression system. The biologics direction was set.

The next two decades built the biosimilars franchise: ALZUMAb (psoriasis, 2013); CANMAb, India's first biosimilar trastuzumab (2014); the Mylan and then Viatris global commercialisation partnership; the 2021 Semglee approval as the first interchangeable biosimilar insulin in the US; and the defining 2022 Biocon Biologics acquisition of the Viatris biosimilars business at US$3.34 billion. The parallel Syngene International business, founded in 1993 and listed separately, became a CDMO that works with eight of the top 10 global pharma companies.

Why the commercial engine is the interesting part

By FY2025 Biocon reports revenue of about ₹16,470 crore on operating income of about ₹4,374 crore and net income of about ₹1,013 crore. Three engines sit under one P&L, each on a different cadence. Biocon Biologics runs branded specialty biosimilars in the US, EU and Japan, with cycles that depend on payer access, hospital formularies and large-customer renewals. Syngene runs a global CDMO with multi-year contract value and a different sales motion. The parent's Indian formulations and global API business is a third, more classical pharma engine. The integration of the Viatris business across regulatory, commercial and supply layers is still in progress, which is part of why FY2025 net income looks compressed relative to revenue.

The next chapter

The 2021 Serum Institute alliance gave Biocon access to about 100 million vaccine doses a year for 15 years in exchange for 15% of Biocon Biologics. The 2022 Viatris acquisition vertically integrated the biosimilars value chain. The question now is whether Biocon Biologics' specialty branded engine in the US and EU compounds fast enough to define the company alongside the legacy small-molecule and Syngene tracks. Pipeline depth and payer-access momentum on Semglee and other interchangeable biosimilars will decide the answer.

It will not be more dashboards. The next advantage is intelligence: every Indian diabetes rep on INSUGEN walking in already knowing what shifted in this endocrinologist's biosimilar prescribing this fortnight, every Biocon Biologics US team separating a payer-channel slip from a formulary one in time to act, every Syngene commercial review focused on the two or three large-client renewal decisions that decide the year. The first generation of Indian pharma built access. The second built scale. The next will build intelligent commercial operations. That is the future PharmaOS is built for.